Cuba will begin clinical trials with drug to treat Alzheimer’s disease
For the first time in Cuba, the patient will undergo a molecular and a clinical diagnosis for this disease.

Author: Gladys Leydis Ramos López | internet@granma.cu
july 20, 2022 11:07:49

Cuba will soon begin a Phase III clinical trial of NeuralCIM, the commercial name of NeuroEPO, the Cuban drug against Alzheimer’s disease, for which the classification of the patients who will participate in the study began in Havana

Although this preliminary screening does not mean the full start of the clinical trial, it is an important step to advance in the correct diagnosis of patients and in the identification of the population to be included, explained to the press Dr. Kalet León Monzón, first deputy director of the Center for Molecular Immunology (CIM).

Patients interested in being evaluated to be included in the clinical trial can request an appointment in the Medical-Surgical Research Center (CIMEQ), and the Salvador Allende, Manuel Fajardo and Hermanos Ameijeiras hospitals, and the Institute of Neurology.

Dr. Leslie Perez Ruiz, promoter of the Alzheimer clinical trial at the CIM, explained that there is currently a database of more than 400 patients, of which 371 are from Havana.

She stated that they have located 310 of the caregivers, who can call and are assigned an appointment for a consultation, which will identify whether the patient has a mild/moderate Alzheimer’s pattern.

According to Dr. Perez Ruiz, phase III of the study is likely to begin next September or October and seeks to evaluate the efficacy and safety of this nasal administration formulation.

In this regard, she explained that NeuralCIM will be compared with Donepezil, a drug approved since by the U.S. Drug Regulatory Agency the 1990s. Meanwhile, for the first time in Cuba, the patient will undergo a molecular and a clinical diagnosis for Alzheimer’s disease.

She said that a phase IV trial will be carried out in the rest of the country, in patients with mild/moderate phenotype of the disease (amnesic variant), and whose diagnosis will only be clinical.

Dr. Perez Ruiz also stated that the drug will be applied by the caregiver at home, who will be trained in the health institutions for the correct administration of NeuralCIM.

Translated by ESTI